Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response.
Immunization coverage is critical to eradicating potentially deadly diseases while reducing the burden of disease. Safe, cost-effective, and patient-friendly injectable drug delivery systems play a crucial role in the success of global vaccination programs. PharmaJet leverages innovative jet injection technology to offer a needle-free, accurate, and more comfortable method of vaccine delivery. With unparalleled ease-of-use…
Needle-free Injection technology has evolved significantly over the last 50 years and is now accepted in many routine immunization settings as a safe and effective vaccine delivery method. Disposable syringe jet injectors are now being used for the delivery of vaccines to eradicate polio, MMR, and influenza, and are showing promising results in vaccine clinical…
The Lancet recently published a study that demonstrates that the delivery of a Zika virus vaccine with the PharmaJet Stratis Needle-free Jet injector resulted in a higher immune response as compared with administration via needle and syringe.
Administration of intradermal fractional dose of inactivated poliovirus vaccine (fIPV) has proven to be safe and immunogenic; however, intradermal injection using needle and syringe is technically difficult and requires trained personnel.
The polio eradication endgame strategic plan calls for the sequential removal of Sabin poliovirus serotypes from the trivalent oral poliovirus vaccine (tOPV), starting with type 2, and the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV), to maintain an immunity base against poliovirus type 2.
ONdrugDELIVERY publishes PharmaJet Study
Offering needle-free technology in a workplace influenza immunization program has the potential to help address an unmet need for increasing workplace health immunization rates.
A randomized controlled trial was conducted in Cuba to determine immune responses after one fractional dose (0.1mL or 1/5 the dose size) of inactivated poliovirus vaccine using the PharmaJet Tropis jet Injector, as compared to a full dose (0.5mL) with traditional needle and syringe intradermal technique.
The Lancet recently published a study that demonstrates that the delivery of an influenza vaccine with the PharmaJet Needle-Free Jet injector compares favorably to a traditional needle and syringe delivery. This is the first definitive non-inferiority study to measure the immune responses to all three influenza viruses induced after administration of a seasonal flu vaccine by a jet injection device as compared to a needle and syringe.
In the fall of 2014, nearly 400 individuals were surveyed about their experience receiving a PharmaJet Stratis® Needle-Free flu shot during the University of Tennessee Flu Shot day. Subjects were overwhelmingly accepting and the data suggests that needle-free vaccination through jet injection may be widely accepted in the general adult population and expand vaccination rates.